SECURITIES EXCHANGE AGREEMENT Effective as of August 24, 2022Securities Exchange Agreement • September 12th, 2022 • Scott John K Jr. • In vitro & in vivo diagnostic substances • Ohio
This Securities Exchange Agreement (this “Agreement”) is being entered into by John K. Scott, Jr. (the “Holder”), and Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the Holder’s subscription to purchase up to 2,400 Units (the “Purchased Units”) pursuant to and subject to the terms set forth in that certain Registration Statement on Form S-1, Registration No. 333-262691, as amended (the “Registration Statement”) and a Prospectus Supplement No. 1 dated August 18, 2022 (the “Prospectus Supplement”). Capitalized terms used but not defined herein have the definitions given to them in the Registration Statement.
